Results 251 to 260 of about 189,595 (350)

Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy

, 2000
James D. Douketis, Gary Foster, Mark Crowther, Martin H. Prins, J S Ginsberg   +4 more
openalex   +1 more source

Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR‐Reduced

European Journal of Heart Failure, EarlyView.
Empagliflozin effects and heart failure outcomes in patients with heart failure with reduced ejection fraction and atrial fibrillation or sinus rhythm. AF, atrial fibrillation; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; SE, standard error ...
Michael Böhm, Javed Butler, Amr Abdin, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Martina Brueckmann, Anne Pernille Ofstad, Elke Schueler, Christoph Wanner, Faiez Zannad, Stefan D. Anker, Milton Packer, on behalf of the EMPEROR‐Reduced Trial Committees and Investigators   +13 more
wiley   +1 more source

Ferric derisomaltose augments intrinsic skeletal muscle electron transport chain activity in heart failure: A FERRIC‐HF II molecular substudy

European Journal of Heart Failure, EarlyView.
FERRIC‐HF II molecular substudy. FDI, ferric derisomaltose. Aims Skeletal muscle energetic augmentation might be a mechanism via which intravenous iron improves symptoms in heart failure, but no direct measurement of intrinsic mitochondrial function has been performed to support this notion.
Mohamad F. Barakat, Nelson Amaral, Daniel Brayson, George Amin‐Youssef, Huda Abu‐Own, Salma Ayis, Francesco Papalia, Fadi Jouhra, Adam Nabeebaccus, Mark Monaghan, Gerry Carr‐White, Alison Sleigh, Geoffrey Charles‐Edwards, Ajay M. Shah, Graham J. Kemp, Andrew J. Murray, Darlington O. Okonko   +16 more
wiley   +1 more source

Bleeding Risk During Colorectal Endoscopic Mucosal Resection With Continued Anticoagulant Therapy: A Multicenter Study. [PDF]

Cureus
Kobayashi S, Harada K, Nawa T, Fujisawa T, Ueki T, Nasu J, Morito Y, Toyokawa T, Inaba T, Kita M, Takenaka R, Inoue M, Higashi R, Tsuduki T, Matsubara M, Yamasaki Y, Okada H, Otsuka M.   +17 more
europepmc   +1 more source

Beta‐blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes

European Journal of Heart Failure, EarlyView.
In total, 5084 patients from Swedish registries with both heart failure (HF) with reduced ejection fraction (HFrEF) and chronic obstructive pulmonary disease (COPD) were included. Confounding was handled by overlap weighting based on propensity scores for beta‐blocker use. Patients were followed up for 5 years, or until death, emigration from Sweden or
Benedikt N. Beer, Lina Benson, Christian Basile, Benedikt Schrage, Peter Moritz Becher, Stefan Blankenberg, Paulus Kirchhof, Barna Szabó‐Söderberg, Marco Metra, Anne Lindberg, Egidio Imbalzano, Giuseppe M. C. Rosano, Patric Karlström, Peter G.M. Mol, Raffaele Scorza, Lars H. Lund, Felix Lindberg, Gianluigi Savarese   +17 more
wiley   +1 more source

Prognostic factors in hospitalized patients with COVID-19 pneumonia and effectiveness of prophylactic anticoagulant therapy: a single-center retrospective study. [PDF]

BMC Infect Dis
He X, Zhang C, Ji J, Liu Y, Feng W, Luo L, Fan H, Guo L.   +7 more
europepmc   +1 more source

Intraocular haemorrhage associated with anticoagulant therapy

, 2000
Clifford R. Weir, Daniel J. Nolan, D Holding, H M Hammer   +3 more
openalex   +1 more source

European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

European Journal of Heart Failure, EarlyView.
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects.
Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, Antoni Bayes‐Genis, Claudio Borghi, Elisabetta Cerbai, Gheorghe A. Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Juan Carlos Kaski, Roland Klingenberg, Joao Morais, William Parker, Mark C. Petrie, Bianca Rocca, Anne Grete Semb, Michele Senni, Christian Sohns, Patrick Sulzgruber, Juan Tamargo, Marco Metra, Michael Böhm, Dobromir Dobrev, Samuel Sossalla   +24 more
wiley   +1 more source

Plasma D-dimer and prothrombin fragment 1+2 in evaluating the occurrence of venous thromboembolism in advanced cancer patients and the effect of preventive anticoagulant therapy. [PDF]

J Med Biochem
Huang Y, Xu Y, Ke C, Zhang B, Zhong Y, Fu H.   +5 more
europepmc   +1 more source

Optimal Treatment of Non-traumatic Intracerebral Hemorrhage Associated with Anticoagulant Therapy

, 2000
Mikihiko Takeshita, Takakazu Kawamata, Toshiyuki Sasaki, Masahiro Izawa, Tomokatsu Hori   +4 more
openalex   +2 more sources